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Summary
Haemophilia is a hereditary X-linked recessive disorder 
caused by a deficiency of either clotting factor VIII 
(haemophilia a) or IX (haemophilia B). Conventional 
treatment is currently based on the use of either plasma 
derived or recombinant coagulation factors. this paper 
reports on the case of a patient with severe haemophilia 
who presented with mesial decay and interproximal 
tartar build-up, for which extraction and scaling to 
remove tartar deposits were indicated. Following 
extraction, the usual haemostasis techniques were 
applied, and postoperative prophylactic antihaemophilic 
treatment was indicated for 2 or 3 days. the patient 
presented with moderate bleeding for a few minutes 
immediately after the procedure. administration of factor 
VIII before surgery as well as the patient’s favourable 
pharmacokinetic response allowed for an optimal result. 
this treatment has afforded patients with haemophilia 
a better quality of life, and safe and efficient access to 
invasive surgical procedures.
CaSe preSenTaTion 
Haemophilia is a hereditary X-linked recessive 
disorder caused by a deficiency of either clot-
ting factor VIII (haemophilia A) or IX (haemo-
philia B).1 2 The prevalence of haemophilia A (also 
known as classic haemophilia) is estimated at 1 in 
6000 men while that of haemophilia B (or Christmas 
disease) has a prevalence of 1 in 30 000 men. The 
size of cDNA is 7056 base pairs (bp) for factor VIII 
and 1389 bp for factor IX. Consequently, the size of 
the protein is 280 kDa for factor VIII and 68 kDa 
for factor IX. The reference plasma level is 200 ng/
mL for factor VIII and 5000 ng/mL for factor IX. 
The half-life of these proteins is very short, which 
means they have a high turnover (around 12 hours 
for factor VIII and 20 hours for factor IX). These 
proteins are mainly synthesised in the liver and, 
to a lesser extent, in the kidney and endothelium. 
The pathological condition is considered severe 
when factor plasma levels fall below 1% of normal; 
moderate when levels range between 1% and 
5%; and mild when factor activity is between 5% 
and 40%. The overall prevalence of the disease is 
7.7/100 000, which means it is considered a rare 
haematologic disorder (Orpha No ORPHA448).
The clinical characteristics of both types of 
haemophilia are similar: spontaneous or traumatic 
haemorrhages; muscle haematomas; haemophilic 
arthropathy caused by recurrent bleeding into target 
joints; and bleeding into the CNS. Without suitable 
exogenous clotting factor replacement therapy 
these manifestations of the disease could result in 
disabling or even deadly sequelae, which negatively 
impact patients’ quality of life and reduce their life 
expectancy.2
Until the 1960s, haemophiliac patients were 
treated with blood or plasma to compensate for 
their deficit in clotting factors. The low plasma 
concentration of coagulation factors made it neces-
sary to administer large volumes of replacement 
factors with the consequent problems derived from 
hypervolaemia. Subsequently, the advent of more 
refined techniques for purifying these proteins 
made it possible to obtain purer and more concen-
trated products, with a very notable reduction in the 
quantities to be injected and in the levels of contam-
inating proteins, which often resulted in anaphy-
lactic reactions. As a result, patients’ quality of life 
was significantly improved. These plasma proteins, 
isolated by immunoprecipitation techniques with 
monoclonal antibodies, were first developed in 
1982 and are still being used for the treatment of 
haemophilia A and B.2
The landmark event that opened the door to the 
current recombinant treatment of haemophilia was 
the isolation and cloning of the genes that produce 
clotting factor VIII (1984) and clotting factor IX 
(1985).2 From that moment onwards, recombinant 
technology made it possible to prepare replacement 
factors from mammalian and human cells, rather 
than human plasma, avoiding the notorious infec-
tions by emerging pathogens that had caused so 
much havoc to HIV patients in the 1980s.
At present, patients with haemophilia benefit 
from optimised treatment protocols based on 
systemic intravenous administration of clotting 
factors, either prophylactically or on demand. 
Conventional treatment is currently based on either 
plasma derived products, duly treated with heat 
and detergent to inactivate lipid coated viruses, or 
high purity recombinant coagulation factor concen-
trates devoid of human or animal proteins.3 4 There 
is almost universal consensus that recombinant 
products should be the treatment of choice.5
Infections with emerging pathogens (HIV, hepa-
titis C virus, prions, etc) in patients with haemo-
philia6–10 have contributed towards making these 
recombinant products universally available, as 
2 Liras a, romeu L. BMJ Case Rep 2019;12:e227974. doi:10.1136/bcr-2018-227974
Global health
these products are highly efficient and offer high safety levels 
against such infections. In addition, they allow for an easy and 
effective dosing strategy as a result of their efficient control of 
in vivo recovery and a longer half-life,11 which has also made 
haemophiliac patients eligible for several invasive surgical proce-
dures.12 13
Most patients with severe and hereditary haemorrhagic disor-
ders were unable to benefit from the dental procedures they 
required, which often resulted in delays in the diagnosis and 
management of their dental conditions. Barriers to proper dental 
care were multifactorial and attributable to either the patient or 
the physician.
A case in point is that of adults older than 45 years. During 
their childhood or adolescence, these patients could benefit from 
neither plasma derived nor recombinant products. As a result, in 
their middle-age, they cannot help fearing that the currently avail-
able procedures could result in an increased bleeding risk, which 
more often than not has led to the neglect of dental care and to 
high proportions of untreated conditions, typically causing pain 
and resulting in complications following invasive dental proce-
dures, such as root canal treatment or extractions.14
This paper reports on the case of a patient with severe haemo-
philia with a very good response to antihaemophilic treatment, 
who presented with mesial decay in the radicular and infragin-
gival area of the upper left third molar as well as marginal gingi-
vitis and tartar build-up in interproximal areas. Extraction of 
the involved tooth and scaling were indicated. Treatments based 
on recombinant factor concentrates have played a decisive role 
in improving the quality of life of haemophiliac patients by 
providing them with safe and efficient access to invasive surgical 
procedures, and particularly dental procedures.
Case report
The patient was a 60-year-old Caucasian man with severe type 
A haemophilia (<1% factor VIII) who presented to the dental 
clinic with pain in the upper left third molar (tooth No 28). The 
tooth was buccally displaced with food impaction on its mesial 
surface. There was decay in the mesial radicular and infragingival 
areas, which made extraction of the tooth advisable. He experi-
enced a throbbing sensitivity to cold, which took a few seconds 
to subside, and exhibited marginal gingivitis and tartar build-up 
in interproximal areas, particularly on the lingual aspect of the 
lower incisors. Scaling was indicated.
He had no deleterious habits but reported a family history 
of type 1 and 2 diabetes mellitus. He had moderate hyperten-
sion, treated with 20 mg of enalapril maleate every 24 hours, and 
dyslipidaemia, treated with 5 mg of rosuvastatin every 24 hours. 
Laboratory results were as follows: glucose 88 mEq/L; aspartate 
transaminase 46 IU/L; alanine transaminase 52 IU/L; gamma-glu-
tamyltransferase 141 IU/L; bilirubin 0.58 mg/dL; haemoglobin 
17.5 g/dL; creatinine 1.22 mg/dL; platelets 418 000/μL; CD4 
528/μL; high density lipoprotein 33 mg/dL; low density lipopro-
tein 103 mg/dL; cholesterol 163 mg/dL; triglycerides 132 mg/dL; 
glomerular filtration rate 63 mL/min; and serum vitamin D defi-
ciency 18 ng/mL (treated with 266 μg hydroferol every 15 days).
He was being treated on demand with 50 IU/kg of ADVATE 
recombinant factor VIII (Baxalta Belgium Manufacturing 
SA). ADVATE (octocog alfa human coagulation factor VIII) is 
synthesised in Chinese hamster ovary cells using recombinant 
DNA technology. As a third generation recombinant factor, no 
exogenous human or animal derived proteins are used in the 
cell culture, purification, or final formulation processes. The 
product is indicated for intravenous administration.
The number of units administered is expressed in international 
units (IUs), the WHO’s standard for factor VIII products. Factor 
VIII activity in plasma may be expressed either as a percentage 
(relative to normal human plasma) or in IUs (relative to the 
international standard for factor VIII in plasma); 1 IU of factor 
VIII activity corresponds to the amount of factor VIII present in 
1 mL of normal human plasma, which means that the required 
dose of factor VIII must be determined using the following 
formula: required IUs=body weight (kg)×desired factor VIII 
rise (%)×0.5. This formula is based on the principle that 1 IU 
of factor VIII per kg of body weight increases plasma factor 
VIII activity by 2 IU/dL. Evaluation of the immunogenicity and 
type of ‘inhibitor kinetics’ induced by ADVATE is carried out by 
calculating the reduction in clotting factor activity in a mixture 
of an exogenous source of the coagulation factor (eg, normal 
pooled plasma) and potentially inhibitor positive plasma. The 
Nijmegen assay15 is a modification of the Bethesda assay devel-
oped by Kasper et al.16 This modified method has been recom-
mended by the Factor VIII/IX Scientific Subcommittee for FVIII 
Inhibitor Testing of the International Society of Thrombosis and 
Haemostasis17; 1 Nijmegen-Bethesda unit (NBU) is defined as 
the amount of inhibitor that produces 50% residual factor VIII 
activity. A positive inhibitor titre is defined as >1 BU/mL by 
the Bethesda method and by >0.3 NBU/mL by the modified 
Bethesda method.
patient preparation
Three hours before his dental appointment, the patient was 
administered 50 IU/kg of ADVATE recombinant factor VIII, 
which would ensure 100% plasma concentration of the defi-
cient clotting factor. All dental procedures described here were 
performed in a private clinic. Both patient and physician signed 
an informed consent form.
Haematological and coagulation tests
Once the patient signed the required informed consent form, 
blood samples were placed into tubes containing 0.105 M sodium 
citrate in a 1:10 ratio (V/V). Plasma was obtained following centri-
fuging at 2000×g for 20 min. All haemostasis related parameters, 
such as prothrombin time (PT), prothrombin activity, activated 
partial thromboplastin time (aPTT) (cephalin time), and fibrin-
ogen, were calculated in accordance with established standards. 
The HemosIL reagent kit (Instrumentation Laboratory; Bedford, 
Massachusetts, USA) was used according to the manufacturer’s 
instructions. The HemosIL RecombiPlasTin 2G kit was used to 
measure PT and fibrinogen levels, as described by Tripodi.18 The 
HemosIL APTT-SP (liquid) reagent was used to determine the 
value of aPTT, as described by Van de Bresselaar.19 20
The Coamatic (Chromogenix: Instrumentation Laboratory) 
chromogenic assay was used to determine factor VIII concen-
tration and activity levels.21 This method is based on the notion 
that factor X is activated to factor Xa by factor IXa in the pres-
ence of calcium and phospholipids. The reaction is catalysed by 
factor VIII, which may be considered a cofactor. If enough Ca2+ 
and phospholipids are used together with significant levels of 
factors IXa and X, activation of factor X will only depend on 
the amount of factor VIII that is present. Factor Xa hydrolyses 
the S-2765 chromogenic substrate and releases the pNA chro-
mophore, producing a yellowish solution that absorbs light at a 
wavelength of 405 nm. The intensity of the factor Xa generated 
(reflected by the colour intensity of the solution) is proportional 
to the factor VIII activity of the sample. Addition of the I-2581 
synthetic thrombin inhibitor prevents the generated thrombin 
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from hydrolysing the S-2765 substrate. Reagents and substrates 
were reconstituted following the manufacturer’s instructions.
Plasma samples were diluted in a HEPES buffered saline solu-
tion (20 mM HEPES, 145 mM NaCl, pH 7.4) containing 1% 
bovine serum albumin in 10 IU/mL. The result was subjected 
to a 10-fold dilution in factor VIII deficient plasma (Siemens 
Healthcare Diagnostic Products GmbH, Marburg, Germany) 
containing 1 IU/mL of von Willebrand factor. For each analytical 
set, a phial of the WHO’s eighth IS calibrator was equilibrated 
to room temperature for 15 min before reconstitution in 1 mL 
Milli-Q H2O. After reconstitution, the calibrator was kept for 
an additional 15 min at room temperature and was transferred 
to Nunc-Immuno Tubes (Minisorp; Thermo Fischer Scientific, 
Waltham, Massachusetts, USA), where it was stored on ice for 
a maximum of 3 hours. The samples and the calibrator were 
further diluted at 20 mIU/mL in diluents from either the kits 
or bovine serum albumin. Following the manufacturer’s instruc-
tions, several dilutions were subsequently prepared. Calibrator/
samples were mixed with reagents containing factor X, factor 
IXa, (pro)thrombin, phospholipids, and calcium, and incubated 
for a specific time period after which reagent containing factor 
X was added. All reactions were performed at 37°C and absor-
bance at 405 nm was measured continuously on a SpectraMax 
Microplate Reader (Molecular Devices, Sunnyvale, California, 
USA) for 5 min. SoftMax Pro 5.4.1 software (Molecular Devices) 
was used to determine the increase in absorbance over time.
Clinical dental procedure
All routine and specific dental procedures were carried out with 
the utmost care and meticulousness. Scaling was performed 
using a Satelec ultrasonic probe with a No 1 tip, at minimum 
power and with abundant irrigation. Following the removal of 
deposits, teeth were polished using a low speed contra-angle 
handpiece and a rubber cup with Detartrine abrasive paste. 
For the extraction, following a rinse with 2% chlorhexidine, a 
topical anaesthetic gel was applied in both the buccal and palatal 
areas. A lidocaine carpule with 0.012% epinephrine was infil-
trated into the buccal area as anaesthesia. Palatal anaesthesia was 
also applied. The syndesmotomy was performed using a straight 
root elevator, which was also employed for a slight preliminary 
dislocation. The extraction was performed using upper molar 
forceps, chiefly with palatal–buccal and circular movements. 
After the avulsion, a curette was used to ensure that no inflam-
matory tissue remained in the tooth socket. A dressing was 
applied to the wound so that the patient would compress it when 
closing the mouth.
Postoperatively, the patient was advised to compress the cotton 
for at least 1 hour. He was warned against any movement that 
could dislodge the clot and increase bleeding. Spitting, rinsing, 
toothbrushing, and eating or drinking hot foods or beverages 
were all contraindicated for at least 24 hours.
The postoperative antihaemophilic treatment regimen was 
established at 50 IU/kg of factor VIII at 12 hours and subse-
quently every 24 hours for the next 2 days.
Global HealTH problem liST 
One of the most relevant breakthroughs in the history of scien-
tific knowledge was the discovery of DNA by Watson and 
Crick in 1953. This enabled certain proteins to be prepared by 
recombinant techniques for their therapeutic use in clinical prac-
tice. Hundreds of recombinant therapeutic proteins have been 
produced to date by means of the expression of a therapeutic 
gene from a fragment of DNA and have become the therapy of 
choice for many diseases.
Clotting factors VIII and IX are two such proteins. The two 
chief advantages of recombinant drugs are their high efficacy 
and safety against pathogen derived infections. Their pharma-
cokinetic profile is a major boon to their ease of use as their 
well controlled in vivo recovery and longer half-life allow for a 
straightforward and efficient dosing strategy.
Although recombinant products are associated with a 
very favourable pharmacokinetic profile, the behaviour of the 
drug is highly dependent on the characteristics of each patient, 
especially as far as in vivo recovery and half-life are concerned. 
The half-life of factor VIII is around 12 hours, although there 
may be a certain degree of interpatient variability. For that 
reason, it is essential to evaluate the drug’s effects in each patient 
at least once a year in order to establish the optimal dose. In 
this study, the so-called chromogenic or colorimetric analysis 
was used to determine factor VIII plasma levels and conduct the 
required pharmacokinetic analysis.21 22 This is the method of 
choice for diagnosing haemophilia A or B and to establish the 
severity of the disease.
The baseline (pre-factor VIII treatment) coagulation profile of 
the patient was as follows: PT 12.6 s (reference value 8–13 s); 
prothrombin activity 82.7% (reference value 75–120%); aPTT 
(cephalin time) 58.7 s (reference value 24–37 s), and fibrin-
ogen 318 mg/dL (reference value 150–450 mg/dL). As was to be 
expected, only the aPTT value was deviant. The patient’s inhib-
itor titre was below 0.3 NBU/mL.
Figure 1 shows a Bayesian estimation of the patient’s pharma-
cokinetic parameters. Factor VIII levels recovered to 81.9 UI/dL 
at 3 hours and to 22.0 UI/dL at 24 hours from infusion. Clear-
ance was 0.028 dL/h/kg; volume of distribution at steady state 
was 0.5 dL/kg; time to 1% above baseline was 89.0 hours; and 
half-life was 14.5 hours.
Figure 2 shows how the dose was optimised. Arrow A indi-
cates pretreatment factor VIII administration; arrow B indicates 
the length of the dental procedure; arrow C, the onset of the 
recovery period; and arrow D administration of the prophy-
lactic treatment. At the time of the procedure, factor VIII plasma 
levels were higher than 90%, while factor VIII levels remained 
between 40% and 140% throughout the recovery period.
The lack of a clear definition of what constitutes major or 
minor surgery in the context of haemophilia leads to inconsis-
tencies in the management of these patients23 given the fact that 
Figure 1 Bayesian estimation of the patient’s pharmacokinetic 
parameters. The curve illustrates factor VIII activity over time following 
intravenous administration of factor VIII. The grey area represents 
the deviation (±20%) with respect to the general population; (- - -), 
pharmacokinetics in the general population; (♦), patient’s data; (---), 
Bayesian pharmacokinetic estimation.
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there is considerable variability in the categorisation of major 
and minor surgical procedures and a certain overlap in surgical 
nomenclature. Even so, most authors admit that dental surgical 
procedures such as those reported in this study should be consid-
ered major surgery when performed in patients with severe 
haemophilia.24–28 Although the patient in this study was a severe 
haemophiliac and was subjected to a major surgical procedure, 
the same methodology applied to patients with no bleeding 
disorders was used. If a thorough haematological investigation 
is performed, adequate levels of factor VIII are maintained, 
and clotting time is properly monitored, there is no reason why 
routine techniques cannot be used both for scaling procedures 
and extractions. As a precaution, post-extraction compression 
of the surgical site should be maintained for longer than in 
non-haemophiliac patients. Use of tranexamic acid in the gauze 
used for compression and during rinsing in the next few days is 
not indispensable but can be extremely useful as an emergency 
treatment in case the haemorrhage proves impossible to control 
with simple compression. In our case, the patient’s response to 
antihaemophilic therapy was satisfactory, which precluded the 
need for any emergency measures. Clotting times were within 
the ranges expected in a severe haemophiliac with factor cover. 
In other cases, the patient’s poor response or the highly invasive 
nature of the procedure may complicate the recovery process. 
In our patient, postoperative bleeding was within the expected 
range: intense during the extraction procedure but gradually 
decreasing after that. The patient was instructed to present to 
the dental clinic and the haemophilia unit for follow-up 1 month 
after the operation.
Global HealTH problem analySiS
If health education and, particularly, an awareness of the impor-
tance of dental hygiene and regular dental check-ups are essen-
tial to avoid dental disease in the general population, they are 
even more crucial in patients suffering from coagulopathies in 
order to avoid the complications associated to a higher bleeding 
risk. Haematologists and dentists should assist patients and their 
families in identifying the resources they can avail themselves 
of to benefit from adequate dental care. A close relationship 
between haematologists, dentists, oral surgeons, and paediatric 
surgeons is as essential as undergoing annual dental check-ups, 
as oral health is an essential component of overall health.29
As a chronic disease caused by a deficiency in the proteins 
responsible for blood clotting, haemophilia results in sequelae 
affecting mainly the musculoskeletal and nervous systems. It may 
also be associated with multisystem involvement in patients with 
HIV or hepatitis C virus infection. For that reason, the approach 
to these patients should be multidisciplinary.30 During the plan-
ning phase, it must be ascertained that the procedure is carried 
out without complications. The surgical team must be trained to 
manage unforeseen situations and make any necessary changes 
to postoperative protocols.
Under this multidisciplinary perspective, in order to help 
prevent and manage postoperative bleeding in haemophiliac 
patients, the dentist must contact the haematologist before the 
operation to explain the dental procedure he wishes to under-
take, report on the patient’s medical condition, and describe the 
kinds of local postoperative haemostatic measures he intends to 
apply.31 The haematologist will then prescribe the most appro-
priate antihaemophilic treatment with sufficient anticipation 
to ensure that plasma levels of the deficient clotting factor are 
optimal during the procedure.
Specifically, it is recommended31 that factor VIII should 
remain between 50% and 75% of normal levels prior to oral and 
periodontal surgery, and between 75% and 100% before maxil-
lofacial surgery. Before an anterior alveolar nerve block, lingual 
infiltration or floor of mouth injection, replacement therapy 
with an exogenous coagulation factor is required. Restorative, 
prosthodontic, endodontic, and orthodontic treatments are 
considered safe for most patients with bleeding disorders. The 
dentist must immediately inform the haematologist about any 
cases of prolonged bleeding, dysphasia, or speaking or breathing 
difficulties following a dental procedure.
In order to facilitate and optimise dental procedures in patients 
with haemophilia, a tool has recently been developed that is 
capable of quantifying and managing the risk of a dental haem-
orrhage. The purpose is to avoid unnecessary treatments and 
promote multidisciplinary collaboration between the different 
clinical teams in attendance.14 The tool takes into account the 
perception of the invasiveness of the dental procedure and the 
severity of haemophilia (mild, moderate, severe) to stratify 
patients into four groups: no bleeding risk group, low risk 
group, moderate risk group, and high risk group, establishing a 
connection between the invasiveness of the dental treatment, the 
bleeding risk, and the required haemostatic cover.
The past decade has seen a burgeoning of innovative treat-
ment options for haemophilia,32 33 ranging from recombinant 
next generation clotting factors with longer half-lives, to a wide 
range of new approaches and modalities, such as the new subcu-
taneously administered bispecific antibody mimicking factor VIII 
that binds to activated factor IX, which in turn activates factor 
X. Other new developments include liver targeted siRNA, which 
can result in a large enough knockdown of the antithrombin 
Figure 2 Dose optimisation. Prediction of the patient’s factor VIII 
plasma levels. (A) Pre-procedure factor VIII administration. (B) Dental 
procedure. (C) Onset of recovery period. (D) Prophylactic treatment: 
12 hours (D12) and 24 hours (D24). (•) Factor VIII plasma level (>90%) 
at the time of the procedure. Factor VIII remained between 40% and 
140% (- - -) during the recovery period.
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gene to allow significant haemostasis, and an antibody against a 
tissue factor pathway inhibitor that also enhances haemostasis.34
This new therapeutic scenario, described by some authors 
as ‘miraculous’,35 has resulted in improved standards of care 
for persons with haemophilia. The improvement has allowed 
a breaking down of the barriers that prevented these individ-
uals from benefiting from dental procedures, which resulted in 
delays in the diagnosis and management of their dental condi-
tions. More often than not, these barriers were related to fears: 
the fears experienced by dentists, who lacked the experience 
needed to manage these kinds of patients, and those experienced 
by patients, especially older patients, who still remembered the 
times when any procedure, even a minor one, entailed a high 
bleeding risk. These fears led to a situation whereby dental care 
in this group of patients was often neglected, with a high number 
of dental conditions being left untreated, which caused pain and 
added complexity to the procedures, particularly extractions, 
when they were performed. As a result, a high proportion of 
patients with bleeding disorders required continuous dental care, 
often because of their few (if any) visits to the dental clinic,14 
with high rates of decay and gingival disease (83% and 46.7%, 
respectively).
This new therapeutic context has made it possible to use 
conventional techniques in almost all kinds of surgical proce-
dures without increasing the risk of bleeding.
These achievements have been possible as a result of the 
development of recombinant coagulation factors, which have 
become the treatment of choice for the disease. They are highly 
efficient and boast an excellent safety profile. Moreover, their 
well controlled in vivo recovery and longer half-life allow for a 
straightforward and efficient dosing strategy. Given their excel-
lent safety profile against emerging pathogens, they can be used 
at the correct dose without fearing potential contamination.8
A third aspect to be considered with respect to the new 
protocols used for the treatment of haemophilia is the signif-
icant increase observed in patient adherence to regular dental 
check-ups, which used to be practically null.
Finally, the current situation could improve even further when 
advanced therapies, in both their cell and gene based modali-
ties, now still at a budding stage, become established as ‘curative’ 
protocols that replace the current (merely palliative) treatments 
of the disease.36
The recombinant era has revolutionised therapeutic options in 
terms of safety and efficacy. It has also opened up the possibility 
to offer patients personalised and individualised treatments.
As far as haemophilia is concerned, patients with the disease 
currently benefit from safe and highly efficient treatment proto-
cols based on recombinant factors. DNA technology based recom-
binant factors are currently displacing human plasma derived 
clotting factors, which in the 1980s gave rise to one of the 
worst disasters in the history of medicine when several thousand 
people were administered HIV and hepatitis C virus contam-
inated products. This happened because, in spite of being 
asymptomatic, many of the blood donors recruited to achieve 
therapeutically effective factor concentrates had a significant yet 
undetectable emerging pathogen transmission potential. This 
caused thousands of patients to die and made many others avoid 
the use of plasma derived products for fear of contagion. All 
of this resulted in many patients receiving suboptimal treatment 
and made it unfeasible to implement certain treatment protocols, 
particularly surgical ones, prompting the development of arthro-
pathic sequelae and dental conditions, among others.
Prepared without human plasma components, recombinant 
factors have become the treatment of choice for haemophilia 
as their favourable safety profile protects them against viral 
and prionic agents. The most recent recombinant factors are 
particularly efficient as they are obtained from human cells, 
which significantly reduces their immunogenicity, decreases 
patients’ immune responses, and lowers the levels of anti-factor 
antibodies.37
These new developments have allowed a more robust dose 
optimisation given both the greater efficacy of the products used 
and the longer half-life associated with the new coagulation 
factors. This has also impacted the way haemophiliac patients 
are managed in dental practice. The above mentioned pharmaco-
logical benefits of the new products, combined with appropriate 
healthcare education and medical specialisation programmes 
addressed to patients and their families on the one hand, and to 
dental professionals on the other, have minimised the risks asso-
ciated with dental procedures and improved the dental health of 
patients of all ages.38
As a result, currently, there are no significant dental health 
differences between child and adolescent haemophiliac patients 
and their non-haemophiliac counterparts. Differences do 
however exist in the adult patient population given the sequelae 
haemophiliac adult patients have had to put up with as a result of 
patient’s perspective
As a 60-year-old patient with severe type A haemophilia who has 
participated in this study, I have to say that my childhood and 
youth were very hard because there were no treatments with 
coagulation factors. Bleeds were recurrent and joint damage 
turned into severe haemophiliac arthropathy with joint sequelae, 
which have now become disabling. In addition, mild or more 
invasive surgical interventions were almost unthinkable for 
patients like myself.
The current therapeutic scenario for haemophilia has made 
it possible to improve patient management and quality of 
life. It has also made it possible to break down the barriers 
that prevented people like me from benefiting from standard 
treatments. Nowadays, I can safely undergo treatments 
for dental disease with much less risk of bleeding, thanks 
particularly to the advent of the new recombinant factors, which 
have shown themselves to be safer and more effective. Indirectly, 
this has led to increased adherence to prevention protocols and 
periodic reviews.
learning points
 ► In this case report, the patient’s response to anti-
haemophiliac therapy was satisfactory, which precluded the 
need for any emergency measures.
 ► Clotting times were within the ranges expected in a severe 
haemophiliac with factor cover. Postoperative bleeding was 
within the expected range: intense during the extraction 
procedure but gradually decreasing after that.
 ► The past decade has seen a burgeoning of innovative 
treatment options for haemophilia, which have resulted in 
improved standards of care for persons with haemophilia.
 ► The improvement has allowed the use of conventional 
techniques in almost all kinds of surgical procedures without 
resulting in a higher risk of bleeding, increased observed 
patient adherence to regular dental check-ups, and a better 
patient quality of life.
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not having benefited from optimal treatments during their child-
hood and adolescence.39
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